Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study

References

• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Sakata H. Invasive Streptococcus pneumoniae infections in children in Kamikawa and Soya subprefecture, Hokkaido, Japan, 2000-2010, before the introduction of the 7-valent pneumococcal conjugate vaccine. J Infect Chemother 2011; 17:799-802; PMID:21701961; http://dx.doi.org/10.1007/s10156-011-0264-8
   PubMed Web of Science ®Google Scholar
• Nakamura R, Togashi T. Population-based incidence of invasive Haemophilus influenzae and pneumococcal diseases before the introduction of vaccines in Japan. Pediatr Infect Dis J 2013; 32:1394-6; PMID:23804122; http://dx.doi.org/10.1097/INF.0b013e3182a14971
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, Sunakawa K, Ubukata K. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138:61-8; PMID:19538821; http://dx.doi.org/10.1017/S0950268809990239
   PubMed Web of Science ®Google Scholar
• Sakai F, Chiba N, Ono A, Yamagata MS, Ubukata K, Sunakawa K, Takahashi T. Molecular epidemiologic characteristics of Streptococcus pneumoniae isolates from children with meningitis in Japan from 2007 through 2009. J Infect Chemother 2011; 17:334-40; PMID:21161561; http://dx.doi.org/10.1007/s10156-010-0180-3
   PubMed Web of Science ®Google Scholar
• Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Sunakawa K, Ubukata K. Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. Microb Drug Resist 2013; 19:308-15; PMID:23480525; http://dx.doi.org/10.1089/mdr.2012.0180
   PubMed Web of Science ®Google Scholar
• Chiba N, Kobayashi R, Hasegawa K, Morozumi M, Nakayama E, Tajima T, Iwata S, Ubukata K. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. J Antimicrob Chemother 2005; 56:756-60; PMID:16131518; http://dx.doi.org/10.1093/jac/dki302
   PubMed Web of Science ®Google Scholar
• Tanaka J, Ishiwada N, Wada A, Chang B, Hishiki H, Kurosaki T, Kohno Y. Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan. Epidemiol Infect 2012; 140:1111-21; PMID:21875450; http://dx.doi.org/10.1017/S0950268811001592
   PubMed Web of Science ®Google Scholar
• Hotomi M, Billal DS, Kamide Y, Kanesada K, Uno Y, Kudo F, Ito M, Kakehata S, Sugita R, Ogami M, et al. Serotype distribution and penicillin resistance of Streptococcus pneumoniae isolates from middle ear fluids of pediatric patients with acute otitis media in Japan. J Clin Microbiol 2008; 46:3808-10; PMID:18832131; http://dx.doi.org/10.1128/JCM.01782-08
   PubMed Web of Science ®Google Scholar
• Otsuka T, Kitami O, Kondo K, Ota H, Oshima S, Tsuchiya A, Shirai T, Fujii K, Nakamure M, Shoji Y, et al. Incidence survey of acute otitis media in children in Sado Island, Japan - Sado Otitis Media Study (SADOMS). PLoS One 2013; 8:e68711; PMID:23844235; http://dx.doi.org/10.1371/journal.pone.0068711
   PubMed Web of Science ®Google Scholar
• Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J 2013; 32:984-9; PMID:23538524; http://dx.doi.org/10.1097/INF.0b013e318293007e
   PubMed Web of Science ®Google Scholar
• Sunakawa K, Takeuchi Y, Iwata S. Nontypeable Haemophilus influenzae (NTHi) epidemiology. Kansenshogaku Zasshi 2011; 85:227-37; PMID:21706841
   PubMedGoogle Scholar
• Takakura M, Fukuda Y, Nomura N, Mitsuyama J, Yamaoka K, Asano Y, Sawamura H, Katsuragawa K, Hashido H, Matsukawa Y, et al. Antibacterial susceptibility surveillance of Haemophilus influenzae isolated from pediatric patients in Gifu and Aichi prefectures (2009-2010). Jpn J Antibiot 2012; 65:305-21; PMID:23383433
   PubMedGoogle Scholar
• Prymula R, Schuerman L. Ten-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479-500; PMID:19863240; http://dx.doi.org/10.1586/erv.09.113
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214-22; PMID:23158882
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med 2014; 11:(6): e1001657; PMID:24892763
   PubMed Web of Science ®Google Scholar
• Japan Pediatric Society. Demanding paper regarding change of description of intramuscular administration of inactivated vaccines in package inserts. 2011. Available from: http://www.jpeds.or.jp/uploads/files/saisin_1106273.pdf.
   Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:S66-S76; PMID:19325449
   PubMed Web of Science ®Google Scholar
• Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 2007; 25:1962-8; PMID:17258357
   PubMed Web of Science ®Google Scholar
• Schuerman L, Wysocki J, Tejedor JC, Knuf M, Kim KH, Poolman J. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol 2011; 18:2161-7; PMID:21994351
   PubMedGoogle Scholar
• Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 2013; 19:412-25; PMID:23657429
   PubMed Web of Science ®Google Scholar
• Feavers I, Goldblatt D, Griffiths E, Nahm M, Zhou T. WHO workshop on standardization of pneumococcal opsonophagocytic assay, 25-26 January 2007. Geneva, Switzerland: World Health Organization; 2007.
   Google Scholar
• European Medicines Agency. Synflorix. European Public Assessment Report. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf.
   Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC; Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014; 2:464-71; PMID:24726406
   PubMed Web of Science ®Google Scholar
• Sartori AL, Minamisava R, Afonso ET, Antunes JLF, Bierrenbach AL, Morais-Neto OL, Toscano CM, Andrade AL. Reduction in all-cause otitis-related outpatient visits in children after PCV10 introduction in Brazil [Abstract ISPPD-0244]. pneumonia 2014; 3:240.
   Google Scholar
• Minamisava R, Sgambatti S, Morais-Neto OL, Cristo EB, Escalante JJC, Bierrenbach AL, Andrade AL. Impact of PCV10 introduction on pneumonia mortality rates in Brazil: a time series analysis [Abstract ISPPD-0556]. pneumonia 2014; 3:248.
   Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013; 19:589-97; PMID:23628462
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. SIREVA II Regional Report. 2012. Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953.
   Google Scholar
• Scott JAG, Hammitt LL, Bwanaali T, Morpeth SC, Makumi A, Mburu J, Otiende M, Moisi JC, Karani A, Mlamba A, et al. The impact of introducing 10-valent pneumococcal conjugate vaccine in Kenya on invasive pneumococcal disease among children under 5 years. Poster session presented at: 8^th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-8); 2012 Mar 11-15; Iguaçu Falls, Brazil.
   Google Scholar
• Rinta-Kokko H, Auranen K, Palmu A, Nohynek H, Nuorti P, Siira L, Toropainen M, Virtanen M, Jokinen J. Effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) during ongoing national vaccination programme (NVP) in Finland [Abstract ISPPD-0560]. pneumonia 2014; 3:140-1.
   Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu A, Virtanen MJ, Nohynek H, Toropainen M, Nuorti P. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland. Paper presented at: 8^th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2013 Nov 19-22; Cape Town, South Africa.
   Google Scholar
• Erlendsdóttir H, Haraldsson A, Hrafnkelsson B, Kristinsson KG. An early reduction of invasive pneumococcal infections after PCV-10 immunisation [Abstract ISPPD-0390]. pneumonia 2014; 3:176.
   Google Scholar
• Sigursson S, Kristinsson KG, Erlendsdóttir H, Hrafnkelsson B, Haraldsson A. Acute otitis media and pneumonia in young children in Iceland: an early reduction of incidence after PCV-10 immunization [Abstract ISPPD-0185]. pneumonia 2014; 3:170-1.
   Google Scholar
• Knol MJ, Sanders EAM, Vlaminckx B, de Melker HE, Van der Ende E. Incidence of invasive pneumococcal disease in the Netherlands after introduction of 7-valent and 10-valent pneumococcal conjugate vaccination [Abstract ISPPD-0261]. pneumonia 2014; 3:175.
   Google Scholar
• De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014; 32:1501-6; PMID:24486346
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Wals P. Effectiveness of three pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD) in Quebec, Canada [Abstract ISPPD-0333]. pneumonia 2014; 3:163.
   Google Scholar
• Institute of Environmental Science & Research Limited. Invasive pneumococcal disease reports. 2011-2013. Available at: https://surv.esr.cri.nz/surveillance/IPD.php.
   Google Scholar
• Fletcher MA, Fritzell B. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol 2012; 2012:312935; PMID:22701486
   PubMedGoogle Scholar
• Schuerman L, Borys D, Hoet B, Forsgren A, Prymula R. Prevention of otitis media: now a reality? Vaccine. 2009; 27:5748-54; PMID:19666154
   PubMed Web of Science ®Google Scholar
• Jefferies JM, Macdonald E, Faust SN, Clarke SC. Thirteen-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin 2011; 7:1012-8; PMID:21941097
   PubMed Web of Science ®Google Scholar
• Borys D, Vesikari T, Tregnaghi MW, Sáez-Llorens X, Iwata S, Lommel P, Moreira M, Ruiz-Guiñazú J. Population variability of the immune response following primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) [Abstract ISPPD-0404]. pneumonia 2014; 3:95-6.
   Google Scholar
• Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014; 33 Suppl 2:S119-29; PMID:24336054
   PubMed Web of Science ®Google Scholar
• Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA 2013; 310:930-7; PMID:24002279
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010; 10:4; PMID:20122261
   PubMed Web of Science ®Google Scholar
• Grant LR, O'Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One 2013; 8:e74906; PMID:24086394
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-73; PMID:21492929
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28:S97-S108; PMID:19325452; http://dx.doi.org/10.1097/INF.0b013e318199f61b
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64.
   Google Scholar
• Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009; 28:S109-18; PMID:19325447; http://dx.doi.org/10.1097/INF.0b013e318199f62d
   PubMed Web of Science ®Google Scholar
• Nishi J, Tokuda K, Imuta N, Minami T, Kawano Y. Prospective safety monitoring of Haemophilus influenzae type b and heptavalent pneumococcal conjugate vaccines in Kagoshima, Japan. Jpn J Infect Dis 2013; 66:235-7; PMID:23698486; http://dx.doi.org/10.7883/yoken.66.235
   PubMedGoogle Scholar
• Kimura M, Kuno-Sakai H, Kamiya H, Ueda K, Isomura S, Koike M, Kato T, Ozaki T, Hirose M, Egami T. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Acta Paediatr Jpn 1995; 37:562-74; PMID:8533580; http://dx.doi.org/10.1111/j.1442-200X.1995.tb03378.x
   PubMedGoogle Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206
   PubMedGoogle Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60; PMID:16522777; http://dx.doi.org/10.1128/CVI.13.3.356-360.2006
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI.00289-09
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-22; PMID:9220157
   PubMedGoogle Scholar
• Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518-27; PMID:17034907; http://dx.doi.org/10.1016/j.vaccine.2006.09.029
   PubMed Web of Science ®Google Scholar